Five Prime Announces First Quarter 2016 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Five Prime Therapeutics (FPRX) Tops Q1 EPS by 22c
May 5, 2016 4:53 PM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q1 EPS of ($0.49), $0.22 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $5.26 million.
For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.
... More